...
首页> 外文期刊>Therapeutic advances in respiratory disease. >An update on the efficacy of endobronchial valve therapy in the management of hyperinflation in patients with chronic obstructive pulmonary disease
【24h】

An update on the efficacy of endobronchial valve therapy in the management of hyperinflation in patients with chronic obstructive pulmonary disease

机译:支气管内瓣膜疗法在慢性阻塞性肺疾病患者恶性通气管理中的最新进展

获取原文
           

摘要

Lung volume reduction surgery has been shown to be effective in patients with heterogeneous emphysema, but is also associated with a relatively high perioperative morbidity and mortality. Accordingly, several novel and potentially less invasive methods for bronchoscopic lung volume reduction have been developed. Endobronchial valve (EBV) therapy is one such therapeutic approach in patients with advanced emphysema. It has been the most widely studied technique over the past years and represents an effective treatment option for patients with severe heterogeneous upper- or lower-lobe-predominant emphysema. The choice of EBV therapy largely depends on the distribution of emphysema and the presence or absence of interlobar collateral ventilation. Adequate patient selection and technical success of valve implantation with the intention of lobar exclusion are predictive factors for positive outcomes. This review attempts to highlight the milestones in the development of bronchoscopic lung volume reduction with one-way valve implantation over the past few years.
机译:肺减容术已被证明对异质性肺气肿患者有效,但也与围手术期相对较高的发病率和死亡率有关。因此,已经开发了几种新颖的并且潜在地侵入性较小的用于支气管镜肺体积减小的方法。支气管内瓣膜(EBV)治疗是晚期肺气肿患者的一种治疗方法。过去几年来,它一直是研究最广泛的技术,对于患有严重异质性上叶或下叶为主的肺气肿的患者,它代表了一种有效的治疗选择。 EBV治疗的选择在很大程度上取决于肺气肿的分布以及叶间副通气的存在与否。适当的患者选择和瓣膜植入技术的成功(旨在排除大叶)是积极结果的预测因素。这篇综述试图强调过去几年中单向瓣膜植入术在支气管镜肺减容方面的里程碑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号